# Stabilis

## Ceftriaxone disodium



Kereskedelmi név

| | |
|---|---|
| Acantex | Argentína, Chile |
| Amcef | Mexikó |
| Antibacin | Görögország, Tunézia |
| Aurofox | Argentína, Mexikó |
| Axobat | Olaszország |
| Azatyl | Görögország |
| Baktisef | Törökország |
| Bioteral | |
| Biotrakson | Lengyelország |
| Bixon | Olaszország |
| Bresec | Görögország |
| Cefaday | Törökország |
| Cefonova | Svédország |
| Cefotrix | Ausztria, Dánia, Németország |
| Cefrag | Olaszország |
| Cephaxon | Törökország |
| Davixon | Olaszország |
| Daytrix | Olaszország |
| Deixim | Olaszország |
| Desefin | Törökország |
| Eftry | Olaszország |
| Eqicept | Törökország |
| Farcef | Görögország |
| Fidato | Olaszország |
| Forsef | Törökország |
| Frineg | Olaszország |
| Gladius | Görögország |
| Glorixone | Görögország |
| Kappacef | Olaszország |
| Labilex | Görögország |
| Lendacin | Horvátország, Lengyelország, orosz, Szlovénia |
| Lidacef | Horvátország |
| Mesporin | Portugália, Szaúd-Arábiában |
| Nevakson | Törökország |
| Nilson | Olaszország |
| Novocef | Törökország |
| Oframax | Texte introuvable (616, ), Lengyelország |
| Olisef | Szlovénia |
| Panatrix | Olaszország |
| Pantoxon | Olaszország |

| | |
|---|---|
| Ragex | Olaszország |
| Rocefalin | Spanyolország |
| Rocefin | Brazília, Olaszország |
| Rocephalin | Dánia, Finnország, Norvégia, Svédország |
| Rocephin | Amerikai Egyesült Államok, Dél-Afrikai Köztársaság, Görögország, Hollandia, Kanada, Lengyelország, Portugália, Svájc, Szaúd-Arábiában, Thaiföld, Törökország |
| Rocephine | Belgium, Franciaország, Luxemburg, Marokkó, Németország |
| Sirtap | Olaszország |
| Tartriakson | Lengyelország |
| Tercefon | Ausztria |
| Travilan | Görögország |
| Unacefin | Törökország |
| Valexime | Olaszország |

## Az oldatok stabilitása

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | 20 mg/ml | 2-8°C | | 7 | | | 4922 |
| | | 10 mg/ml | 5°C | | 21 | | | 589 |
| | | 10 & 50 mg/ml | -20°C | | 182 | | | 589 |
| | | 10 & 50 mg/ml | 15°C-32°C | ? | 7 | | | 589 |
| | | 20 mg/ml | 2-8°C | | 28 | | | 1452 |
| | | 20 mg/ml | 25°C | | 24 | | | 432 |
| | | 20 mg/ml | 25°C | ? | 5 | | | 1452 |
| | | 50 mg/ml | 5°C | | 35 | | | 589 |
| | | 10 mg/ml | 15°C-32°C | ? | 7 | | | 589 |
| | | 10 mg/ml | 5°C | | 84 | | | 589 |
| | | 10 & 50 mg/ml | -20°C | | 182 | | | 589 |
| | | 20 mg/ml | 25°C | | 48 | | | 432 |
| | | 50 mg/ml | 15°C-32°C | ? | 24 | | | 589 |
| | | 50 mg/ml | 5°C | | 56 | | | 589 |
| | Phenol 0,04% | 20 mg/ml | 2-8°C | | 2 | | | 4922 |
| PVC | | 40 mg/ml | 23°C | ? | 3 | | | 640 |
| PVC | | 40 mg/ml | 4°C | | 30 | | | 640 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| PVC | | 2 mg/ml | -20°C | | 14 | | | | 587 |
| PVC | | 2 mg/ml | 20°C | ? | 14 | | | | 587 |
| PVC | | 2 mg/ml | 4°C | | 14 | | | | 587 |
| PVC | | 40 mg/ml | 23°C | ? | 1 | | | | 640 |
| PVC | | 40 mg/ml | 4°C | | 14 | | | | 640 |
| PE | | 20 mg/ml | -20°C | ? | 98 | | | | 2110 |
| PE | | 20 mg/ml | 2-8°C | ? | 14 | | | | 2110 |
| POF | | 20 mg/ml | 2-8°C | | 28 | | | | 1452 |
| POF | | 20 mg/ml | 25°C | ? | 5 | | | | 1452 |
| EVA | | 10 & 20 mg/ml | 23°C | | 3 | | | | 1840 |
| EVA | | 10 & 20 mg/ml | 4°C | | 30 | | | | 1840 |
| PP | | 100 mg/ml | -20°C | | 180 | | | | 100 |
| PP | | 100 mg/ml | 20°C | | 5 | | | | 100 |
| PP | | 100 mg/ml | 4°C | | 40 | | | | 100 |
| PP | | 100 mg/ml | 8°C | | 13 | | | | 1638 |
| PP | | 20 mg/ml | 2-8°C | | 7 | | | | 4922 |
| PP | | 10 & 40 mg/ml | -15°C | | 10 | | | | 259 |
| PP | | 10 & 40 mg/ml | -15°C | | 10 | | | | 259 |
| PP | | 250 & 450 mg/ml | -15°C | | 56 | | | | 279 |
| PP | | 250 & 450 mg/ml | 20°C | | 24 | | | | 279 |
| PP | | 250 & 450 mg/ml | 4°C | | 10 | | | | 279 |
| PP | | 250 mg/ml | -15°C | | 56 | | | | 279 |
| PP | | 250 & 450 mg/ml | 20°C | | 24 | | | | 279 |
| PP | | 250 & 450 mg/ml | 4°C | | 10 | | | | 279 |
| PP | Phenol 0.04% | 20 mg/ml | 2-8°C | | 2 | | | | 4922 |
| PI | | 5 & 40 mg/ml | 25°C | ? | 24 | | | | 604 |
| PI | | 5 & 40 mg/ml | 4°C | | 10 | | | | 604 |

## A keverékek stabilitása

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | 20 mg/ml | 25°C | | Clindamycin phosphate : 12 mg/ml | 8 | 432 |
| | | 20 mg/ml | 25°C | | Clindamycin phosphate : 12 mg/ml | 1 | 432 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| PVC | | 10 mg/ml | 24-26°C | ? | Metronidazole : 7,5 mg/ml | 24 | 11 |
| PVC | | 10 mg/ml | 4-6°C | | Metronidazole : 7,5 mg/ml | 72 | 11 |
| PVC | | 10 mg/ml | 24-26°C | ? | Metronidazole : 7,5 mg/ml | 24 | 11 |
| PVC | | 10 mg/ml | 4-6°C | | Metronidazole : 7,5 mg/ml | 72 | 11 |
| PVC | | 10 mg/ml | 25°C | ? | Metronidazole : 5 mg/ml | 3 | 649 |
| PVC | | 10 mg/ml | 8°C | ? | Metronidazole : 5 mg/ml | 72 | 282 |
| PP | | 450 mg/ml | -15°C | | Lidocaine hydrochloride : 10 mg/ml | 56 | 279 |
| PP | | 450 mg/ml | 20°C | | Lidocaine hydrochloride : 10 mg/ml | 24 | 279 |
| PP | | 450 mg/ml | 4°C | | Lidocaine hydrochloride : 10 mg/ml | 10 | 279 |
| | | 40 mg/ml | 25°C | ? | Paracetamol : 10 mg/ml | 4 | 3571 |
| ? | | 16,7 mg/ml | 22°C-28°C | ? | Daptomycin : 16,7 mg/ml | 2 | 1937 |

## Stabilitást befolyásoló tényezők

| | | | | | |
|---|---|---|---|---|---|
| | | | | | 589 |
| | RL | | | | 1744 |
| | RL | | | | 3523 |
| | | | | | 2238<br>3523 |
| | | | | | 3523 |
| | | | | | 100 |

## Kompatibilitás

| | | | | |
|---|---|---|---|---|
| | | Ceftriaxone disodium : 20 mg/ml<br>Amifostine : 10 mg/ml | | 3 |
| | | Ceftriaxone disodium<br>Amikacin sulfate | | 3523 |
| | | Ceftriaxone disodium : 20 & 40 mg/ml<br>Aminophylline : 1 & 4 mg/ml | | 276 |
| | | Ceftriaxone disodium : 20 & 40 mg/ml<br>Aminophylline : 1 & 4 mg/ml | | 276 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Amsacrine : 1 mg/ml | | 253 |
| | | Ceftriaxone disodium | | 3523 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Aciclovir sodium : 5 mg/ml | | 336 |

| | | | | |
|---|---|---|---|---|
| | | Ceftriaxone disodium : 20 mg/ml<br>Amiodarone hydrochloride : 6 mg/ml | | 1611 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Amoxicillin sodium / clavulanic acid : 100/10 mg/ml | | 3824 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml | | 921 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Anidulafungin : 0.5 mg/ml | | 1982 |
| | | Ceftriaxone disodium : 66.7 mg/ml<br>Azithromycine : 2 mg/ml | | 1800 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Aztreonam : 40 mg/ml | | 99 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Bivalirudin : 5 mg/ml | | 1713 |
| | | Ceftriaxone disodium : 50 mg/ml<br>Blinatumomab : 0.125 & 0.375 µg/ml | | 3976 |
| | | Ceftriaxone disodium<br>Calcium glucoheptonate | | 3523 |
| | | Ceftriaxone disodium<br>Calcium gluconate | | 4964 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Caspofungin acetate : 0.5 mg/ml | | 2233 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Caspofungin acetate : 0,7 mg/ml | | 2247 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Ceftolozane / tazobactam : 10/5 mg/ml | | 3828 |
| | | Ceftriaxone disodium | RL | 1744 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Allopurinol sodium : 3 mg/ml | | 307 |
| | | Ceftriaxone disodium : 100 mg/ml | | 939 |
| | | Ceftriaxone disodium : 100 mg/ml | NaH CO3 | 150 |
| | | Ceftriaxone disodium<br>Calcium chloride | | 3523 |
| | | Ceftriaxone disodium<br>Calcium gluconate | | 3644 |
| | | Ceftriaxone disodium<br>Calcium gluconate | | 2302 |
| | | Ceftriaxone disodium | 10 | 3523 |
| | | Ceftriaxone disodium : 20 mg/ml | | 301 |
| | | Ceftriaxone disodium<br>Amsacrine | | 3523 |
| | | Ceftriaxone disodium<br>Calcium gluconate | | 3523 |
| | | Ceftriaxone disodium | | 3523 |
| | | Ceftriaxone disodium | RL | 3523 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Caffeine : 10 mg/ml | ∅ | 3964 |
| | | Ceftriaxone disodium : 20 mg/ml | | 1415 |

| | | | | |
|---|---|---|---|---|
| | | Ceftriaxone disodium : 10 mg/ml | | 4440 |
| | | Ceftriaxone disodium<br>Amikacin sulfate | | 3549 |
| | | Ceftriaxone disodium | | 3523 |
| | | Ceftriaxone disodium | | 2238 |
| | | Ceftriaxone disodium | 0.45 2.5 | 3523 |
| | | Ceftriaxone disodium : 100 mg/ml | RL | 4603 |
| | | Ceftriaxone disodium | | 3523 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Ceftolozane / tazobactam : 10/5 mg/ml | | 3828 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Cisatracurium besylate : 0.1 >> 5 mg/ml | | 299 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Clindamycin phosphate : 12 mg/ml | | 432 |
| | | Ceftriaxone disodium<br>Clindamycin phosphate | | 3526 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Clindamycin phosphate : 12 mg/ml | | 432 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Cloxacillin sodium : 100 mg/ml | | 3012 |
| | | Ceftriaxone disodium : 16,7 mg/ml<br>Daptomycin : 16,7 mg/ml | | 1937 |
| | | Ceftriaxone disodium<br>Daptomycin | | 2271 |
| | | Ceftriaxone disodium<br>Daunorubicin/cytarabine liposomale : 0,4 mg/mL | | 4654 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Defibrotide : 8 mg/ml | | 3728 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Dexmedetomidine : 4 µg/ml | | 1712 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Diltiazem hydrochloride : 5 mg/ml | | 198 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Docetaxel : 0.9 mg/ml | | 1754 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Doxorubicin hydrochloride liposome peg : 0.4 mg/ml | | 251 |
| | | Ceftriaxone disodium<br>Erythromycin lactobionate | | 3674 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Etoposide phosphate : 5 mg/ml | | 1410 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Famotidine : 2 mg/ml | | 215 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Fenoldopam mesylate : 80 µg/ml | | 1803 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Filgrastim : 30 µg/ml | | 244 |
| | | Ceftriaxone disodium<br>Fluconazole | | 3523 |

| | | | | |
|---|---|---|---|---|
| | | Ceftriaxone disodium : 40 mg/ml<br>Fluconazole : 2 mg/ml | | 496 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Fludarabine phosphate : 1 mg/ml | | 492 |
| | | Ceftriaxone disodium<br>Folinate calcium | | 3523 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Foscarnet sodium : 24 mg/ml | | 1135 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Foscarnet sodium : 24 mg/ml | | 1135 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Fosfomycin : 30 mg/ml | | 4055 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Fosfomycin : 30 mg/ml | | 4055 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Gallium nitrate : 1 mg/ml | | 91 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Gemcitabine hydrochloride : 10 mg/ml | | 1423 |
| | | Ceftriaxone disodium<br>Gentamicin sulfate | | 3523 |
| | | Ceftriaxone disodium<br>Gentamicin sulfate | | 3520 |
| | | Ceftriaxone disodium<br>Gentamicin sulfate | | 3643 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Granisetron hydrochloride : 0.05 mg/ml | | 182 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Heparin sodium : 50 UI/ml | | 317 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Hetastarch : 60 mg/ml | | 1721 |
| | | Ceftriaxone disodium : 10 & 50 mg/ml<br>Insulin aspart : 1 UI/ml | | 1508 |
| | | Ceftriaxone disodium : 10 & 50 mg/ml<br>Insulin aspart : 1 UI/ml | | 1508 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Isavuconazonium sulfate : 1.5 mg/ml | | 3829 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Isavuconazonium sulfate : 1.5 mg/ml | | 3829 |
| | | Ceftriaxone disodium<br>Kanamycin sulfate | | 3523 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Ketoprofene : 3.2 mg/ml | | 1847 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Labetalol hydrochloride : 5 & 2,5 mg/ml | | 241 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Labetalol hydrochloride : 5 & 2,5 mg/ml | | 241 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Labetalol hydrochloride : 5 & 2,5 mg/ml | | 241 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Lansoprazole : 0.55 mg/ml | | 1625 |
| | | Ceftriaxone disodium<br>Levofolinate calcium | | 3523 |

| | | | | |
|---|---|---|---|---|
| | | Ceftriaxone disodium<br>Levofolinate calcium | RL | 3523 |
| | | Ceftriaxone disodium : 10 mg/ml<br>Linezolid : 2 mg/ml | ∅ | 1659 |
| | | Ceftriaxone disodium<br>Linezolid | | 3560 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Linezolid : 2 mg/ml | ∅ | 1925 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Melphalan : 0.1 mg/ml | ▲ | 169 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Meropenem : 50 mg/ml | ● | 4319 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Methotrexate sodium : 30 mg/ml | ▲ | 150 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Metronidazole : 15 mg/ml | ▲ | 11 |
| | | Ceftriaxone disodium : 10 mg/ml<br>Metronidazole : 5 mg/ml | ∅ | 282 |
| | | Ceftriaxone disodium : 10 mg/ml<br>Metronidazole : 7.5 mg/ml | ▲ | 11 |
| | | Ceftriaxone disodium : 10 mg/ml<br>Metronidazole : 7.5 mg/ml | ◆ | 11 |
| | | Ceftriaxone disodium : 10 mg/ml<br>Metronidazole : 5 mg/ml | ∅ | 649 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Metronidazole : 15 mg/ml | ◆ | 11 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Milrinone lactate : 0,2 mg/ml | ◆ | 4144 |
| | | Ceftriaxone disodium : 20 & 40 mg/ml<br>Morphine sulfate : 1 mg/ml | ◆ | 62 |
| | | Ceftriaxone disodium<br>N-acetylcysteine : 200 mg/ml | ∅ | 3766 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Naloxone hydrochloride : 0.4 mg/ml | ∅ | 3408 |
| | | Ceftriaxone disodium<br>Netilmicin sulfate | | 3523 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Paclitaxel : 1.2 mg/ml | ◆ | 248 |
| | | Ceftriaxone disodium : 0,22 mg/ml | ▲ 0.225<br>◆ 3.75 | 4693 |
| | | Ceftriaxone disodium : 20 >> 40 mg/ml<br>Pantoprazole sodium : 0.16 >> 0.8 mg/ml | ▲ | 1902 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Paracetamol : 10 mg/ml | | 4742 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Paracetamol : 10 mg/ml | ∅ | 3571 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Pemetrexed disodium : 20 mg/ml | ▲ | 1953 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Pentamidine isetionate : 3 mg/ml | ◆ | 275 |
| | | Ceftriaxone disodium : 20 & 40 mg/ml<br>Pethidine hydrochloride : 10 mg/ml | ◆ | 62 |

| | | | | |
|---|---|---|---|---|
| | | Ceftriaxone disodium : 20 mg/ml<br>Phloroglucinol : 2,5 mg/ml | | 3791 |
| | | Ceftriaxone disodium<br>Plazomicin sulfate | | 3523 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Plazomicin sulfate : 24 mg/ml | | 4145 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Propofol : 10 mg/ml | | 300 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Remifentanil hydrochloride : 25 & 250 µg/ml | | 59 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Salbutamol sulfate : 1 mg/ml | | 3216 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Sargramostim : 10 µg/ml | | 335 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Sodium bicarbonate : 14 mg/ml | | 150 |
| | | Ceftriaxone disodium<br>Streptomycin sulfate | | 3523 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Sulbactam/durlobactam : 15/15 mg/ml | | 4801 |
| | | Ceftriaxone disodium : 40 mg/ml<br>Tacrolimus : 1000 µg/ml | | 479 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Tedizolid phosphate : 0.8 mg/ml | | 3827 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Telavancin hydrochloride : 7.5 mg/ml | | 3254 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Telavancin hydrochloride : 7.5 mg/ml | | 3254 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Teniposide : 0.1 mg/ml | | 905 |
| | | Ceftriaxone disodium : 20 & 40 mg/ml<br>Theophylline : 4 mg/ml | | 276 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Theophylline : 4 mg/ml | | 317 |
| | | Ceftriaxone disodium : 20 & 40 mg/ml<br>Theophylline : 4 mg/ml | | 276 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Thiopental sodium : 25 mg/ml | | 3767 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Thiotepa : 1 mg/ml | | 249 |
| | | Ceftriaxone disodium<br>Tobramycin sulfate | | 3523 |
| | | Ceftriaxone disodium : 1 >> 250 mg/ml<br>Vancomycin hydrochloride : 20 mg/ml | | 1674 |
| | | Ceftriaxone disodium : 100 mg/ml<br>Vancomycin hydrochloride : 20 mg/ml | | 95 |
| | | Ceftriaxone disodium<br>Vancomycin hydrochloride | | 3523 |
| | | Ceftriaxone disodium : 1 >> 250 mg/ml<br>Vancomycin hydrochloride : 2 mg/ml | | 1674 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Vinorelbine tartrate : 1 mg/ml | | 84 |

| | | | | |
|---|---|---|---|---|
| | | Ceftriaxone disodium : 20 mg/ml<br>Warfarin sodium : 2 mg/ml | | 315 |
| | | Ceftriaxone disodium : 20 mg/ml<br>Zidovudine : 4 mg/ml | | 337 |

## Az alkalmazás módja

## Irodalom

| | Type | publikáció |
|---|---|---|
| 3 | Napló | Trissel LA, Martinez JF.<br>Compatibility of amifostine with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 11 | Napló | Bailey LC, Orosz ST.<br>Stability of ceftriaxone sodium and metronidazole hydrochloride.<br>Am J Health-Syst Pharm 1997 ; 54: 424-427. |
| 59 | Napló | Trissel LA, Gilbert DL, Martinez JF, Kim MC.<br>Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 62 | Napló | Pugh CB, Pabis DJ, Rodriguez C.<br>Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 123-125. |
| 84 | Napló | Trissel LA, Martinez JF.<br>Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1994 ; 51: 495-499. |
| 91 | Napló | Lober CA, Dollard PA.<br>Visual compatibility of gallium nitrate with selected drugs during Y-site injection.<br>Am J Hosp Pharm 1993 ; 50: 1208-1210. |
| 95 | Napló | Pritts D, Hancock D.<br>Incompatibility of ceftriaxone with vancomycin.<br>Am J Hosp Pharm 1991 ; 48: 77. |
| 99 | Napló | Trissel LA, Martinez JF.<br>Compatibility of aztreonam with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 100 | Napló | Plumridge RJ, Rieck AM, Annus TP, Langton SR.<br>Stability of ceftriaxone sodium in polypropylene syringes at -20, 4, and 20°C.<br>Am J Health-Syst Pharm 1996 ; 43: 2320-2323. |
| 150 | Napló | Aujoulat P, Coze C, Braguer D, Raybaud C.<br>Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.<br>J Pharm Clin 1993 ; 12: 31-35. |
| 169 | Napló | Trissel LA, Martinez JF.<br>Physical compatibility of melphalan with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1993 ; 50: 2359-2363. |

| | | |
|---|---|---|
| 182 | Napló | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 198 | Napló | Gayed AA, Kheshary PR, Hinkle RL.<br>Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 215 | Napló | Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.<br>Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.<br>Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 241 | Napló | Leader WG, Jones JM.<br>Incompatibility between ceftriaxone sodium and labetolol hydrochloride.<br>Am J Health-Syst Pharm 1996 ; 53: 2639. |
| 244 | Napló | Trissel LA, Martinez JF.<br>Compatibility of filgrastim with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 | Napló | Trissel LA, Martinez JF.<br>Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 | Napló | Trissel LA, Martinez JF.<br>Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 | Napló | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 | Napló | Trissel LA, Chandler SW, Folstad JT.<br>Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 259 | Napló | Bailey LC, Tang KT, Medwick T.<br>Stability of ceftriaxone sodium in infusion-pump syringes.<br>Am J Hosp Pharm 1993 ; 50: 2092-2094. |
| 275 | Napló | Lewis JD, El-Gendy A.<br>Cephalosporin-pentamidine isethionate incompatibilities.<br>Am J Health-Syst Pharm 1996 ; 53: 1461-1462. |
| 276 | Napló | Parrish MA, Bailey LC, Medwick T.<br>Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures.<br>Am J Hosp Pharm 1994 ; 51: 92-94. |
| 279 | Napló | Bailey LC, Cappel KM, Orosz ST.<br>Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes.<br>Am J Hosp Pharm 1994 ; 51: 2159-2161. |
| 282 | Napló | Rivers TE, Webster AA.<br>Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags.<br>Am J Health-Syst Pharm 1995 ; 52: 2568-2570. |
| 299 | Napló | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 | Napló | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |

| | | |
|---|---|---|
| 301 | Napló | Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.<br>Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 | Napló | Trissel LA, Martinez JF.<br>Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 315 | Napló | Bahal SM, Lee TJ, McGinnes M, Dobler GL.<br>Visual compatibility of warfarin sodium injection with selected medications and solutions.<br>Am J Health-Syst Pharm 1997 ; 54: 2599-2600. |
| 317 | Napló | Kershaw BP, Monnier HL, Mason JH.<br>Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.<br>Am J Hosp Pharm 1993 ; 50: 1360-1362. |
| 335 | Napló | Trissel LA, Bready BB, Kwan JW, Santiago NM.<br>Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 | Napló | Forman JK, Lachs JR, Souney PF.<br>Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 337 | Napló | Bashaw ED, Amantea MA, Minor JR, Galleli JF.<br>Visual compatibility of zidovudine with other drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 432 | Napló | Marble DA, Bosso JA, Townsend RJ.<br>Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions.<br>Am J Hosp Pharm 1986 ; 43: 1732-1736. |
| 479 | Napló | Min DI, Brown T, HWang GC.<br>Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 492 | Napló | Trissel LA, Parks NPT, Santiago NM.<br>Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 | Napló | Lor E, Sheybani T, Takagi J.<br>Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1991 ; 48: 744-746. |
| 587 | Napló | Smith BR.<br>Effect of storage temperature and time stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection.<br>Am J Hosp Pharm 1983 ; 40: 1024-1025. |
| 589 | Napló | Kedzierewicz F, Finance C, Nicolas A, Dixneuf P, Hoffman M.<br>Stability of parenteral ceftriaxone disodium solutions in frozen and liquid states: effect of freezing and microwave thawing.<br>J Pharm Sci 1989 ; 78: 73-77. |
| 604 | Laboratórium | Stabilité des médicaments dans l'Intermate® SV50, 100, 200<br>Baxter 1998 |
| 640 | Napló | Walker SE, Dranitsaris G.<br>Stability of reconstituted ceftriaxone in dextrose and saline solutions.<br>Can J Hosp Pharm 1987 ; 40: 161-166. |
| 649 | Napló | Das Gupta V.<br>Stability of ceftriaxone sodium when mixed with metronidazole injection.<br>Int J Pharm Compound 1997 ; 1: 280-281. |

| | | |
|---|---|---|
| 905 | Napló | Trissel LA, Martinez JF.<br>Screening teniposide for Y-site physical incompatibilities.<br>Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 | Napló | Trissel LA, Gilbert DL, Martinez JF.<br>Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.<br>Hosp Pharm 1998 ; 33: 284-292. |
| 939 | Napló | Gilbar PJ, Groves CF.<br>Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.<br>Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1135 | Napló | Baltz JK, Kennedy P, Minor JR, Gallelli J.<br>Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1990 ; 47: 2075-2077. |
| 1410 | Napló | Trissel LA, Martinez JF, Simmons M.<br>Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 | Napló | Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.<br>Compatibility of medications with 3-in-1 parenteral nutrition admixtures.<br>JPEN 1999 ; 23: 67-74. |
| 1423 | Napló | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1452 | Napló | Muller HJ, Howe K, Frank C, Haker I.<br>Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*.<br>Eur Hosp Pharm 2000 ; 6: 17-23. |
| 1508 | Napló | Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.<br>Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.<br>EJHP 2015 ;22:123-124. |
| 1611 | Napló | Chalmers JR, Bobek MB, Militello MA.<br>Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.<br>Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1625 | Napló | Trissel LA, Saenz C, Williams YW, Ingram D.<br>Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2001 ; 5: 314-321. |
| 1638 | Napló | O'Connell C, Sabra K, Scott K.<br>Stability of reconstituted ceftriaxone solution in polypropylene syringes.<br>Eur Hosp Pharm 1996 ; 2: 47-48. |
| 1659 | Napló | Xu QA, Trissel LA, Williams KY.<br>Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics.<br>J Am Pharm Assoc 2000 ; 40: 509-514. |
| 1674 | Napló | Trissel LA, Gilbert DL, Martinez JF.<br>Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration.<br>Hosp Pharm 1998 ; 33: 1515-1522. |
| 1712 | Napló | Trissel LA, Saenz CA.<br>Compatibility screening of Precedex during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 | Napló | Trissel LA, Saenz CA.<br>Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 311-315. |

| | | |
|---|---|---|
| 1721 | Napló | Trissel LA, Williams KY, Baker MB.<br>Compatibility screening of Hextend during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2001 ; 5: 69-72. |
| 1744 | Napló | Burkiewicz JS.<br>Incompatibility of ceftriaxone sodium with lactated Ringer's injection.<br>Am J Health-Syst Pharm 1999 ; 56: 384. |
| 1754 | Napló | Trissel LA, Gilbert DL, Wolkin AC.<br>Compatibility of docetaxel with selected drugs during simulated Y-site administration.<br>Int J Pharm Compound 1999 ; 3: 241-244. |
| 1800 | Napló | Voytilla KL, Tyler LS, Rusho WJ.<br>Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.<br>Am J Health-Syst Pharm 2002 ; 59: 853-855. |
| 1803 | Napló | Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.<br>Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1840 | Napló | Xu QA, Trissel LA, Saenz CA et al.<br>Stability of three cephalosporin antibiotics in autodose infusion system bags.<br>J Am Pharm Assoc 2002 ; 42: 428-431. |
| 1847 | Napló | Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G.<br>Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration.<br>J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241. |
| 1902 | Napló | Walker SE, Wyllie A, Law S.<br>Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.<br>Can J Hosp Pharm 2004 ; 57, 2: 90-96. |
| 1925 | Napló | Trissel LA , Williams KY, Gilbert DL.<br>Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.<br>J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1937 | Napló | Lai JJ, Brodeur SK.<br>Physical and chemical stability of daptomycin with nine medications.<br>Ann Pharmacotherapy 2004 ; 38: 1612-1616. |
| 1953 | Napló | Trissel LA, Saenz CA, Ogundele AB, Ingram DS.<br>Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 | Napló | Trissel LA, Ogundele AB.<br>Compatibility of anidulafungin with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2110 | Napló | Hecq JD, Evrard JM, Vanbeckbergen DF, Jamart J, Galanti LM.<br>Effect of freezing, long term storage and microwave thawing on the stability of ceftriaxone sodium in 5% dextrose infusion polyolefin bags at 2-8°C.<br>EJHP Science 2006 ; 12, 3: 52-56. |
| 2233 | Napló | Condie C.K, Tyler L.S, Barker B, Canann D.M.<br>Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery<br>Am J Health-Syst Pharm 2008 ; 65, 5: 454-457. |
| 2238 | Laboratórium | Clinomel - Résumé des caractéristiques du produit<br>Baxter 2018 |
| 2247 | Napló | Chan P, Heatherly K, Kupiec T.C, Trissel L.A.<br>Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2271 | Laboratórium | Daptomycine (Cubicin®) Résumé des caractéristiques du produits<br>Novartis 2006 |

| | | |
|---|---|---|
| 2302 | Laboratórium | Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium. |
| 3012 | Napló | Sullivan HF, Forrest JM, Leclair G.<br>Antibiotics 30 November 2008 2008 ; 61, 5: 356-357.<br>Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration<br>Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3216 | Napló | Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.<br>Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.<br>Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3254 | Napló | Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.<br>Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration<br>Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3408 | Napló | Tollec S, Touzin K, Pelletier E, Forest J.M.<br>Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels.<br>Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3520 | Laboratórium | Cidomycin - Summary of product Chracteristics.<br>Sanofi 2011 |
| 3523 | Laboratórium | Ceftriaxone (Rocephin®) - Summary of Product Characteristics.<br>Roche 2018 |
| 3526 | Laboratórium | Clindamycin (Dalacin®) - Summary of Product Characteristics<br>Pharmacia 2010 |
| 3549 | Laboratórium | Amikacine B Braun - Résumé des caractéristiques du produit.<br>B Braun 2012 |
| 3560 | Laboratórium | Linezolid (Zyvox®) - Summary of Product Characteristics<br>Pharmacia 2013 |
| 3571 | Napló | Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.<br>Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.<br>Hosp Pharm 2014 ; 49, 1: 42-47. |
| 3643 | Laboratórium | Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics<br>Sanofi 2015 |
| 3644 | Laboratórium | Calcium gluconate® - Summary of Product Characteristics<br>Hameln Pharmaceuticals 2010 |
| 3674 | Laboratórium | Erythromycin lactobionate - Summary of Product Characteristics<br>PanPharma 2016 |
| 3728 | Napló | Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.<br>Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2014 ; 71: 1288-1291. |
| 3766 | Napló | Forrest J.M, Hildgen P.<br>Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels<br>Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 | Napló | Legris M.E, Lavoie A, Forrest J.M, Hildgen P.<br>Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.<br>Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3791 | poszter | Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.<br>Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.<br>Apifh Congress, Paris November 2014 2014 |
| 3824 | Napló | Boudi S, Roy H, Forest JM, Leclair G.<br>Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.<br>Pharmactuel 2023 2023;56,3:91-98 |

| | | |
|---|---|---|
| 3827 | poszter | Ghazi I.M, Hamada Y, Nicolau D.P.<br>Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.<br>ASHP Midyear 2015 |
| 3828 | poszter | Thabit A.K, Hamada Y, Nicolau D.P.<br>Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.<br>ASHP Midyear 2015 |
| 3829 | poszter | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.<br>Compatibility of isavunazonium sulfate during simulated Y-site administration.<br>ASHP Midyear 2015 |
| 3964 | Napló | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.<br>Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.<br>Pharmactuel 2017 ; 50,1 : 27-33. |
| 3976 | Napló | Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.<br>Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |
| 4055 | Napló | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.<br>Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4144 | Napló | Ross A, Boddu S, Mauro V, Churchwell M.<br>Physical compatibility of milrinone with levofloxacin and ceftriaxone injection.<br>EJHP 2018 ;75,14:1010-1012 |
| 4145 | Napló | Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.<br>Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4319 | Napló | Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.<br>Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.<br>Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4440 | Napló | Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.<br>Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.<br>Ann Nutr Metab 2018 ; 73: 227-233. |
| 4603 | Napló | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.<br>Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.<br>Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4654 | poszter | Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.<br>Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.<br>Communication personnelle 2021 |
| 4693 | Napló | Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L.<br>Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection.<br>Drug Design Dev Ther 2022 ;16:1433-1440. |
| 4742 | Napló | Macoviciuc M, Nguyen C, Forest J-M, Leclair G.<br>Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y.<br>Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 | Napló | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.<br>Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2024 ;51,1: |
| 4922 | Napló | Wanandy T, Handley SA, Le TTA, Lau WY, Turner ME, Wiese MD.<br>Stability of Antibiotics for Use in the Testing of Immediate Drug Allergy Reactions.<br>J Allergy Clin Immunol Pract 2024 13, 2: 343-352. |
| 4964 | Laboratórium | GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit.<br>B BRAUN MELSUNGEN AG 2019 |

# Stabilis

# Ceftriaxone disodium

## Stabilitása gyógyszerészeti készítmények

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | 100 mg ® = Mylan | vazelin >> 1 ml | -20°C | | 90 | | | 4916 |
| | | 100 mg ® = Mylan | injekcióhoz való víz >> 1 ml | -20°C | | 90 | | | 4916 |

## Irodalom

| | Type | publikáció |
|---|---|---|
| 4916 | Napló | Gondé H, Belaid I, Lamoureux F, Martinet J Varin R, Tétart F, Hervouët C.<br>Stability Over Time of In-Hospital-Compounded Amoxicillin Capsules and Ceftriaxone Patch Tests for Drug Allergy Testing.<br>J Investig Allergol Clin Immunol 2023 ;33(4):292-294. |

# Szótár

| | | | |
|---|---|---|---|
| | Antibiotikum | | Injekció |
| | Kereskedelmi név | | Az oldatok stabilitása |
| | Csomagolás | | Molekula |
| | Koncentráció | | Hőmérséklet |
| | Tárolás | | A stabilitás időtartama |
| | biohasonló | | ellentmondó adatok |
| | Irodalom | | Üveg |
| | Injekcióhoz való víz | | Fénytől védve tartandó |
| | Nap | | 0,9% nátrium-klorid |
| ? | Nincs meghatározva | | Fény |
| | Óra | | 5% glükóz |
| | NaCl 0.9% + fenol 0.4% | PVC | Poli(vinilklorid) |
| PE | Polietilén | POF | Poliolefin |
| EVA | Etilén-vinilacetát | | fecskendő polipropilén |
| | Injekcióhoz való víz + antibakteriális szer | PI | Poliizoprén elasztomer |
| | A keverékek stabilitása | | Oldószer |
| | Vegyület | Ø | Egy sem |
| PP | Polipropilén | ? | Nincs meghatározva |
| | Stabilitást befolyásoló tényezők | | Előidéz |
| | Stabilitás  növekedés | RL | Ringer-laktát oldat |
| | Lecsapódás | | Lebomlás |
| | Parenterális táplálás (lipid) | | Parenterális táplálás (lipid-mentes) |
| | Növekedés | | Kompatibilitás |
| | Összeegyeztethető | | Meghatározatlan összeférhetetlenség |
| | Összeegyeztethetetlen | | Kémiai instabilitás |
| | Azonnali csapadék | | A zavarosság elvesztése |
| NaH CO3 | NaHCO3 | 10 | 10% glükóz |
| | NaCl 0,45% glükóz 2,5% | | Csapadék 1 óra után |
| | egyedi oldószer | | Azonnali zavarosság |
| 0.225 3.75 | NaCl 0,225% + glükóz  3.75% | | Az alkalmazás módja |

| | | | |
|---|---|---|---|
| | Intravénás | | Intravénás infúzió |
| | Intramuszkuláris | | Irodalom |
| | kenőcs | | Stabilitása gyógyszerészeti készítmények |
| | Origine | | segédanyag |
| | Injekcióhoz való üveg | | Szótár |